Theravance Biopharma, Inc. (TBPH) · Aug 25, 2026 · Other events

Theravance keeps ampreloxetine alive after CYPRESS miss, but FDA demands another pivotal trial

FDA path remains open — FDA says current data do not support approval; additional pivotal trial may offer a path

Post hoc analyses strengthen the biological signal, yet FDA says the current package cannot support approval. A new pivotal trial is the only path forward.

The failed primary endpoint remains the central fact. CYPRESS did not achieve statistical significance on its week-8 OHSA primary endpoint, and the key secondary endpoint showed a similar late-period deterioration. 〔0〕 (Executive Summary for CYPRESS Study 0197) The miss was already public, along with the company’s decision to wind down the program, so this filing is not a fresh clinical success surprise.

AreaFiling read
Primary endpointNot statistically significant (Executive Summary for CYPRESS Study 0197)
Secondary endpointsSimilar trends at week 8 (Executive Summary for CYPRESS Study 0197)
Confirmed symptomatic nOH post hoc populationOHSA treatment difference -1.06; OHDAS -1.27; OHQ -1.24, all statistically significant (Average Treatment Effects)
FDA positionCurrent package does not support approval; another pivotal trial could offer a path (FDA Interactions)
Next regulatory stepType C meeting requested on future study design (FDA Interactions)

The new information is that the program is not completely dead. Theravance’s focused, longitudinal post hoc analysis found statistically significant treatment differences across OHSA, OHDAS, and OHQ in a 47-patient subgroup, while blood-pressure, heart-rate, and norepinephrine changes preserved evidence of biological activity. (Average Treatment Effects; Plasma Norepinephrine Levels; Blood Pressure and Heart Rate Responses) 〔1〕 (Executive Summary for CYPRESS Study 0197)

The FDA signal is constructive but heavily qualified. The agency said the existing clinical package cannot support approval, but acknowledged that an additional pivotal trial leveraging prior data could create a potential path forward. 〔2〕 (FDA Interactions) That is better than a definitive regulatory dead end, but it replaces the hoped-for filing with another expensive, uncertain study.

Net: modestly better than the post-miss baseline, not a recovery of the original thesis. The market already knew the trial had failed and that ampreloxetine was being wound down; the incremental value here is regulatory optionality, not approval-ready evidence. The FDA’s willingness to discuss a future study is therefore a narrow positive, while the explicit rejection of the current package caps the read.

What to watch next

FDA Type C meeting on future study design

Original filing on SEC EDGAR

More Theravance Biopharma, Inc. news

Theravance keeps ampreloxetine alive after CYPRESS miss, but FDA demands another pivotal trial | TBPH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.